Tristan J. Huie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tristan J. Huie has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Anna Neumeier
Formerly Denver Health Medical Center , Denver, CO
3 shared publications - Joshua J. Solomon
Center for Interstitial Lung Disease, National Jewish Health, Denver, CO, USA
3 shared publications - Timothy Amass
University of Colorado, Division of Pulmonary Sciences and Critical Care Medicine; Denver Health Medical Center
3 shared publications - David A. Lynch
Department of Radiology, National Jewish Health, Denver, Colo
2 shared publications - Evans R. Fernández Pérez
Center for Interstitial Lung Disease, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health , Denver, CO
2 shared publications - Jeffrey James Swigris
Center for Interstitial Lung Disease, National Jewish Health, Denver, Colorado; and
2 shared publications
Latest Publications
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A1506
Quantitative High-Resolution Computed Tomography Predicts Progressive Pulmonary Fibrosis
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A1506
Quantitative High-Resolution Computed Tomography Predicts Progressive Pulmonary Fibrosis
- Open Access
- 3 May 2021
- Published by Oxford University Press (OUP)
- p. A1683
Extraneous Load Events Correlate with Cognitive Burden Amongst Multidisciplinary Providers During Intensive Care Unit Rounds
- 3 May 2021
- Published by Oxford University Press (OUP)
- p. A1683
Open AccessExtraneous Load Events Correlate with Cognitive Burden Amongst Multidisciplinary Providers During Intensive Care Unit Rounds
- Open Access
- 22 April 2021
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 7 (2)
Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
Hypersensitivity pneumonitis (HP) is an immunologically mediated form of lung disease resulting from inhalational exposure to any of a large variety of antigens. A subgroup of patients with HP develops pulmonary fibrosis (fibrotic HP; FHP), a significant cause of morbidity and mortality. This study will evaluate the safety and efficacy of the antifibrotic pirfenidone in treating FHP.This single-centre, randomised, double-blind, placebo-controlled trial is enrolling adults with FHP (ClinicalTrials.gov:NCT02958917). Study participants must have fibrotic abnormalities involving ≥5% of the lung parenchyma on high-resolution computed tomography scan, forced vital capacity (FVC) ≥40% and diffusing capacity of the lung for carbon monoxide ≥30% of predicted values. Study participants will be randomised in a 2:1 ratio to receive pirfenidone 2403 mg·day−1or placebo. The primary efficacy end-point is the mean change in FVC % predicted from baseline to week 52. A number of secondary end-points have been chosen to evaluate the safety and efficacy in different domains.
- 22 April 2021
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 7 (2)
Open AccessDesign and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
Hypersensitivity pneumonitis (HP) is an immunologically mediated form of lung disease resulting from inhalational exposure to any of a large variety of antigens. A subgroup of patients with HP develops pulmonary fibrosis (fibrotic HP; FHP), a significant cause of morbidity and mortality. This study will evaluate the safety and efficacy of the antifibrotic pirfenidone in treating FHP.This single-centre, randomised, double-blind, placebo-controlled trial is enrolling adults with FHP (ClinicalTrials.gov:NCT02958917). Study participants must have fibrotic abnormalities involving ≥5% of the lung parenchyma on high-resolution computed tomography scan, forced vital capacity (FVC) ≥40% and diffusing capacity of the lung for carbon monoxide ≥30% of predicted values. Study participants will be randomised in a 2:1 ratio to receive pirfenidone 2403 mg·day−1or placebo. The primary efficacy end-point is the mean change in FVC % predicted from baseline to week 52. A number of secondary end-points have been chosen to evaluate the safety and efficacy in different domains.
- 15 May 2019
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 199 (10) , 1284-1287
Increasing Hypersensitivity Pneumonitis–related Mortality in the United States from 1988 to 2016
- 15 May 2019
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 199 (10) , 1284-1287
Increasing Hypersensitivity Pneumonitis–related Mortality in the United States from 1988 to 2016